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Summary
The primary objective of Paget’s disease treatment is the relief
of symptoms, but treatment is also commonly prescribed to
prevent the development of late complications in asympto-
matic subjects with active disease (i.e., above normal serum
alkaline phosphatase [bALP]). An aggressive course of treat-
ment is recommended before surgery at the site of a pagetic
lesion, the aim being to reduce as much as possible the vas-
cularity of the lesion. 
Bisphosphonates are considered the therapy of choice and the
only realistic therapeutic option. All the new bisphosphonates
(tiludronate, clodronate, pamidronate, alendronate, risedronate,
ibandronate and zoledronate) appear to provide equivalent ben-
efits. The degree of suppression of disease activity and the pro-
portion of patients in whom normalisation of bALP is achieved
does not depend on the potency of the individual compounds,
but rather on the dose administered and the duration of the
treatment. With these drugs, complete and sustained suppres-
sion of Paget’s activity is achieved in 80% of patients. 
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Introduction
The treatment of Paget’s disease of bone (Paget’s disease) is
based on the use of agents capable of suppressing the abnor-
mal activity of pagetic osteoclasts. Paget’s disease was an un-
treatable condition until the mid-1970s when calcitonin became
available and was registered in most countries for the treatment
of the disease. Calcitonin was administered by subcutaneous
injections at doses (100 IU/day) that were often poorly tolerated.
The treatment proved able to alleviate bone pain within a few
weeks, but the observed decreases in the activity of the dis-
ease, as assessed by bone turnover markers, was often inade-
quate (1). In the early ’80s the bisphosphonate etidronate was
introduced. This had to be used at sub-optimal doses (10
mg/kg/day) because at higher doses etidronate therapy is asso-
ciated with the development of osteomalacic features. Thus, in
a large proportion of patients, neither calcitonin nor etidronate
were able to suppress the disease activity completely. 
These agents were replaced in the ’90s by the newer bisphos-
phonates (clodronate, tiludronate, pamidronate, alendronate
and risedronate), progressively more potent than etidronate,
and potentially able to achieve greater disease suppression
and frank remission (i.e., normalisation of pagetic indices) for
prolonged periods. In addition to these bisphosphonates, oth-
ers have been studied in some countries (olpadronate and ner-
idronate) or are still awaiting final registration (ibandronate,
zoledronate) (2-6). 
In the USA, gallium nitrate was also registered for the treat-
ment of Paget’s disease (7) and there have been some at-
tempts to treat the disease with anti-viral agents. 
In many patients the complications of Paget’s disease require
additional symptomatic treatments, including analgesics, anti-
inflammatory drugs, and selected orthopaedic and neurosurgi-
cal interventions, but here we focus on the treatment of the
metabolic disease. 
Objective and treatment threshold 
The primary objective of Paget’s disease treatment is the relief
of symptoms, and the new bisphosphonates are the agents
most likely to relieve the aches and pain, excessive warmth
over affected bone, headache due to skull involvement, low-
back pain secondary to pagetic vertebral changes, and effects
of nerve compression associated with the condition. Even
though filling in of osteolytic blade-of-grass lesions in weight-
bearing bones has been reported in some treated cases, bone
deformities and secondary osteoarthritic lesions usually remain
unchanged, and loss of hearing is unlikely to improve.
The question of whether or not to institute medical treatment to
prevent the development of late complications in patients
deemed to be at risk is still debated (8-10). In the past, medical
intervention in patients with evidence of active disease (elevat-
ed levels of bone turnover markers) but who were totally
asymptomatic was not considered strictly necessary. This atti-
tude is now changing, for three reasons:
1. Biopsy sample studies have reported restoration of normal
patterns of new bone deposition following suppression of
pagetic activity. This might imply that prolonged suppression
of overactivity can allow full restoration of normal lamellar
bone and eventually a partial resolution of the deformities. 
2. Untreated disease, in which abnormal bone turnover persists
for decades, may be associated with the appearance or
worsening of irreversible bone deformities, and then sympto-
matic disease. This has never been proven, although incom-
plete suppression of elevated indices of bone turnover, on
older therapies, has been associated with disease progres-
sion (11). In this regard, it should be mentioned that pro-
longed treatment with the new bisphosphonates is followed
by a normalisation of indices in most patients. 
3. The safety profile, the general acceptability, and the costs of
treatment with the newer bisphosphonates, especially when
administered intravenously are, in Europe at least, excellent.
This very low cost/benefit ratio has encouraged a less con-
servative attitude to definition of the treatment threshold. 
According to recent recommendations on the management of
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Paget’s disease (8), the presence of asymptomatic but active
disease (i.e., above normal serum alkaline phosphatase – bALP
–) constitutes an indication for treatment aimed at preventing
later complications. Others argue that the evidence does not yet
support such use, because it has not been shown in clinical tri-
als that suppression of the disease reduces progression of the
deformity (9). The need for treatment might be considered more
pressing when the involved skeletal sites are potentially more
likely to give rise to severe problems or complications (e.g.,
weight-bearing bones, areas near major joints, vertebral bodies,
extensive involvement of the skull). In this setting, treatment is
also more warranted in younger patients, who may have to live
with the disease for years. However, even in the elderly, med-
ical treatment is justified in the presence of bone involvement
very close to joints or nerve roots that might quickly (within the
space of a few years) give rise to problems. 
Treatment might also be indicated in some cases with normal
bALP activity but with focal symptoms. We have observed a
few cases presenting small (a phalange, the clavicle, part of
the parietal bone) but very active monostotic lesions, in whom
a first course of treatment relieved symptoms and fully sup-
pressed bALP (even taking it to the lower end of the normal
range). Although the symptoms returned within a few months
(in spite of the bALP value still being well within the normal
range), it was found that they could rapidly be relieved again
with further courses of treatment (Figure 1).
One of the most scarring complications of surgery at the site of
a pagetic lesion is severe blood loss. Although controlled stud-
ies are not available, an intense course of treatment is recom-
mended in this situation, the aim being to reduce as much as
possible the vascularity of the lesion.
Available specific therapies
Bisphosphonates are currently regarded as the treatment of
choice and the only realistic therapeutic option, but in the near
future other therapies (for example, anti-RANKL agents) may
become available. Here we discuss the individual compounds,
considering the evidence of their efficacy and the most com-
monly used therapeutic regimens. With the sole exception of
etidronate, the bisphosphonates appear to provide equivalent
benefits. The degree of suppression of disease activity and the
proportion of patients in whom the normalisation of bALP is
achieved depends not on the potency of the individual com-
pounds but rather on the dose administered and the duration of
the treatment. Attempts to show that patients responding poor-
ly to one compound can respond better to another have been
unconvincing (12). 
E t i d r o n a t e . Etidronate was the first bisphosphonate used for
the clinical treatment of Paget’s disease (13,14). It is still
available in most countries, but is gradually being abandoned
in favour of the new bisphosphonates. Etidronate is commer-
cially available in a 200- or 400-mg tablet. The recommended
r gimen is 5 mg/kg/day (i.e., a daily dose of 400 mg in most
patients, taken at any time of day on an empty stomach) for a
period of 6 months. The main problem associated with
tidronate therapy is the development of mineralisation de-
f c s. All bisphosphonates have the capacity, at high enough
doses, to impair mineralisation of newly forming bone. In the
case of etidronate, the doses that most effectively reduce the
increased bone resorption can also impair mineralisation,
thus making it necessary to administer the compound at sub-
optimal doses, and for no longer than 6 months at a time.
Thus, in the most severe cases, etidronate therapy is able
neither to suppress disease activity adequately nor to relieve
s y m p t o m s .
T i l u d r o n a t e . Tiludronate is about 10 times more potent than
etidronate, and its use at effective doses is not associated with
mi eralisation problems. In most countries it has been regis-
tered for treatment of Paget’s disease as Skelid in a 200-mg
tablet. The recommended dose is 400 mg daily for 3 months,
followed by a 3-month post-treatment observation period, after
which the bALP is likely to have reached its nadir. This ap-
proach led to a normal serum bALP at the 6-month point in a
quarter of moderately affected subjects (15,16). The drug
should be taken with a large glass of water in fasting conditions
(at least 4 h after food) and the patient should avoid lying down
for 30 minutes after ingesting it.
P a m i d r o n a t e . Pamidronate has been available in the Nether-
lands for several decades and worldwide (in an i.v. formulation)
only since the early ’90s. The greater potency of pamidronate
provided a number of advantages over etidronate and tilu-
dronate, which are shared by all the newer, amino-bisphospho-
nates:
a. it allows a majority of patients to obtain normalisation of
pagetic indices rather than the partial suppression that is
seen with calcitonin, etidronate, and (in most cases) tilu-
dronate;
b. the effects may be longer lasting. In some cases with mono-
stotic disease a single treatment course is followed by an
apparent permanent remission and, in most cases, up to a
year or more of disease suppression;
c. with pamidronate, as with all the newer, more potent bispho-
sphonates, the inhibition of mineralisation occurs at doses
several times greater than those recommended for the treat-
ment of Paget’s disease, thus the risk of focal osteomalacia
is markedly reduced;
d. although the oral formulation was investigated in earlier
studies carried out in Leiden by Bijvoet (17), the drug was
eventually developed for the treatment of malignant hyper-
calcaemia, for which the i.v. formulation is considered more
appropriate. Thus, the i.v. formulation remained the pre-
erred – and indeed the only available – formulation in most
European countries. 
Pamidronate has a long history as a treatment for Paget’s
isease and in some countries, where it has been registered
only for the treatment of malignant hypercalcemia, it is still
used off-label in pagetic patients. For these reasons several
dosing regimens have been proposed in the literature (17-
19). Where available with the indication for Paget’s disease,
the package insert for pamidronate, marketed as Aredia, rec-
ommends three daily 4-hour infusions, each of 30 mg in 500
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F i g u r e1 - Changes in pain score (Visual analogue scale, VAS) and in
serum alkaline phosphatase (bALP) after single i.v. infusions of 100 mg
neridronate (arrows) in a patient with focal pagetic lesion of the left pari-
etal bone of the skull. Pain resumed despite persistent normal levels of
bALP and was relieved by each neridronate infusion.
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ml of normal saline or 5% dextrose in water. However, in
clinical practice, on the basis of accumulated experience of
malignant conditions, the most common treatment is a single
60-90 mg infusion in 300-500 ml of 5% dextrose in water giv-
en over a 2-h period. In some patients with more severe dis-
ease (e.g., serum bALP levels 3-10 times normal), multiple
infusions may be required. If the bALP levels are still above
the normal range six months after the initial course of treat-
ment, further infusions may be required in order to achieve
complete biochemical suppression of disease activity. The
most common side effect is the appearance, 24-36 hours af-
ter the first infusion, of a typical acute phase reaction (20)
with low-grade fever and flu-like symptoms. The likelihood
and severity of the acute phase reaction decreases progres-
sively with repeated dosing. Transient hypocalcaemia and
hypophosphataemia with secondary hyperparathyroidism
may result from the intense positive skeletal calcium and
phosphate balance, in relation to the uncoupling between
bone resorption and bone formation. This is proportional to
the Paget’s disease activity and tends to occur with any bis-
phosphonate therapy but it is more evident when bisphos-
phonates are administered intravenously. Hypocalcaemia is
almost invariably asymptomatic if patients are normally vita-
min D repleted. In any case, it is desirable to give oral calci-
um supplements at a dose of 500 mg, two or three times dai-
ly, and vitamin D, 400 to 800 U daily, to prevent or counter a
reduction in serum calcium and concomitant rise in PTH.
There has been one report of asymptomatic mineralisation
abnormalities with dosing in the usual clinical range (21), but
this is not the general experience. Venous irritation may
arise, especially if an insufficient volume of fluid is used or if
the fluid extravasates. The rate of infusion should also be
kept low in order to avoid overconcentration of the drug in
the renal tubuli and renal failure, observed after i.v. infusion
of clodronate and etidronate (22).
A l e n d r o n a t e . Alendronate is available for the treatment of
Paget’s disease in most western countries (Fosamax 40). The
recommended dose is 40 mg daily for 6 months to be taken
with a large glass of water (>200 ml) on getting up in the morn-
ing after an overnight fast. The patient is instructed not to take
anything else orally (except more water) and not to lie down for
at least 30 minutes after ingesting the dose. With this dosing
schedule, a single course of alendronate was found to nor-
malise bALP in over 63% of patients with biochemical remis-
sion lasting for more than 12 months (23-25). Biopsy speci-
mens from patients treated with alendronate revealed normal
patterns of deposition of new bone and radiological improve-
ment (25). The overall tolerability profile is good, although up-
per gastrointestinal discomfort, nausea, or the less common
but more serious complication of oesophageal ulceration, are
not rare. 
Risedronate. Risedronate 30 mg (Actonel 30) was approved by
both FDA and EMEA in 1998 for the treatment of Paget’s dis-
ease. Studies of risedronate have described the efficacy of a
30-mg dose given for 2 (26) or 3 (27) months to patients with
moderately active disease. These short courses of therapy led
to a nearly 80% reduction in bALP and normalisation of bone
turnover markers in 50-70% of patients. The 30-mg risedronate
dose is taken with 200 ml of water on getting up in the morning
after an overnight fast, with no other oral intake (except water)
and no lying down for 30 minutes after the dose. Gastrointesti-
nal side effects of varying degrees of severity are expected in a
minority of patients. 
Other bisphosphonates. Other bisphosphonates have been
registered or used off-label in some countries. Clodronate has
been extensively investigated in the past (1, 28) and it is often
used in several European countries. It is most commonly ad-
ministered intravenously. The highest daily dose that can be
safely infused is 300 mg dissolved in 500 ml saline solution.
The rate of infusion should not exceed 200 mg/hour, in order to
avoid nephrotoxic effects (22). In the moderate-severe cases, 5
to 10 infusions are usually required to achieve a 70% remission
rate. Olpadronate is available only in the Netherlands and in
some countries in South America (3). Neridronate is available
only in Italy. Its potency is similar to that of pamidronate and
the recommended dose is 100 mg in 100 ml saline solution i.v.
for one or two days (4). In several European countries iban-
dronate and zoledronate (5, 6) are used off-label with a single
i.v. bolus of 2 and 4 mg respectively.
Monitoring treatment
Treatment with bisphosphonates is associated with a rapid de-
crease in bone resorption markers. However, these markers
are seldom used to assess treatment efficacy because they al-
so eflect the suppression of normal bone turnover and their
variance is too high (Figure 2). The markers of bone formation
decline more slowly and the nadir is reached only after 6
months. It is worth noting that serum osteocalcin is only mar-
g nally increased in pagetic patients and should not be used for
onitoring treatment (Figure 3).
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F i g u r e2 - Percent changes (means and standard errors) in N-telopep-
tide of collagen type I (dotted line) and in serum alkaline phosphatase
(continuous line) after a single i.v. infusion of 100 mg neridronate at
time zero in 15 patients with active Paget’s disease of bone. 
F i g u r e3 - Time changes (means and standard errors) in serum osteo-
calcin (dotted line) and in serum alkaline phosphatase (continuous line)
after 5 i.v. infusions of 300 mg clodronate (arrow) in 11 patients with
very active Paget’s disease of bone.
FOR
REV
IEW 
ONL
Y
© CI
C ED
IZION
I INT
ERN
AZIO
NALI
References
11. Adami S, Spiazzi G, Marini G, Rosini S, Lo Cascio V. Sequential
treatment of Paget’s disease with human calcitonin and
dichloromethylene-diphosphonate. Metabolic Bone Disease and
Related Research. 1984;5:131-137.
12. Delmas PD, Chapuy MC, Vignon E, Charhon S, Briancon D,
Alexandre C, Edouard C, Meunier PJ. Long-term effects of
dichloromethylene diphosphonate in Paget’s disease of bone. J
Clin Endocrinol Metab. 1982;54:837-844.
13. Gonzalez DC, Mautalen CA. Short term therapy with oral ol-
padronate in active Paget’s disease of bone. J Bone Miner Res.
1999;14:2042- 2047.
14. Adami S, Bevilacqua M, Broggini M, Fillipponi P, Ortolani S,
Palummeri E, Uliveri F, Nannipieri F, Braga V. Short term intra-
venous therapy with neridronate in Paget’s disease. Clin Exp
Rheumatol. 2002;20:55-58.
15. Woitge HW, Oberwittler H, Heichel S, Grauer A, Ziegler R, Seibel
MJ. Short- and long-term effects of ibandronate treatment on bone
turnover in Paget’s disease of bone. Clin Chem. 2000;46:684-690.
16. Buckler H, Fraser W, Hosking D, Ryan W, Maricic MJ, Singer F,
Davie M, Fogelman I, Birbara CA, Moses AM, Lyles K, Selby P,
Richardson P, Seaman J, Zelenakas K, Siris E. Single infusion of
zoledronate in Paget’s disease of bone: a placebo-controlled,
dose ranging study. Bone. 1999;24:81S-85S.
17. Bockman RS, Wilhelm F, Siris E, Singer F, Chausmer A, Bitton
R,Ko tler J, Bosco BJ, Eyre DR, Levenson D. A multi-center trial of
low dose gallium nitrate in patients with advanced Paget’s disease
of bone. J Clin Endocrinol Metab. 1995;80:595-602.
18. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to
the diagnosis and management of Paget’s disease of bone. J
Bone Miner Res. 2001;16:1379-1387.
19. Selby PL, Davie MW, Ralston SH, Stone MD. Guidelines on the
management of Paget’s disease of bone. Bone. 2002;31:366-373.
10. Drake WM, Kendler DL, Brown JP. Consensus statement on the
modern therapy of Paget’s disease of bone from a Western Osteo-
porosis Alliance Symposium. Clin Ther. 2001;23:620-626.
11. Meunier PJ, Vignot E. Therapeutic strategy in Paget’s disease of
bone. Bone. 1995;17:489S-49IS.
12. Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK,
Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN,
Faulkner DL, Geelhoed E, Gan SK, Vasikaran S. Paget’s disease:
acquired resistance to one aminobisphosphonate with retained re-
sponse to another. J Bone Miner Res. 1999;2:79-84.
13. Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN,
Sankey RR. Influence of disodium etidronate on clinical and labo-
ratory manifestations of Paget’s disease of bone (osteitis defor-
mans). N Engl J Med. 1973;289:1379-1384.
14. Canfield R, Rosner W, Skinner J, McWhorter J, Resnick L, Feld-
man F, Kammerman S, Ryan K, Kunigonis M, Bohne W. Disphos-
phonate therapy of Paget’s disease of bone. J Clin Endocrinol
Metab. 1977;44:96-106.
15. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse
HP, Picot C, Titeux L, Reginster JY, Dougados M 1995 Compara-
tive prospective, double-blind, multi-center study of the efficacy of
tiludronate and etidronate in the treatment of Paget’s disease of
bone. Arthritis Rheum. 1995;38:851-858.
16. McClung MR, Tou CK, Goldstein NH, Picot C. Tiludronate therapy
for Paget’s disease of bone. Bone 1995;17:493S-496S.
17. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij
P, Bijvoet OL. Paget’s disease of bone: early and late responses
to three different modes of treatment with aminohydroxypropyli-
dene bisphosphonate (APD). BMJ. 1987;295:1301-1305.
18. Siris ES. Perspectives: A practical guide to the use of pamidronate
in the treatment of Paget’s disease. J Bone Miner Res. 1994;9:
303-304.
19. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ. Ef-
fects of multiple intravenous pamidronate courses in Paget’s dis-
ease of bone. Rev Rhum Engl Ed. 1999;66:467-476.
20. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno
G e Lo Cascio V. The acute-phase response after bisphosphonate
administration. Calcif Tissue Int. 1987;41:326-331.
21. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce
BF. Mineralisation defects with pamidronate therapy for Paget’s
disease. Lancet. 1993;342:1459-1460.
22. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A
comparative review. Drug Safety. 1996;14:158-170.
23. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A,
Lyles K, McIlwain H, Murphy WA Jr., Reda C, Rude R, Seton M,
Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M. Compara-
tive study of alendronate vs. etidronate for the treatment of Paget’s
disease of bone. J Clin Endocrinol Metab. 1996;81:961-967.
24. Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Ko-
towicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A,
Musliner TA, Thompson DE, Yates AJ. Biochemical and radiologic
improvement in Paget’s disease of bone treated with alen-
dronate:a randomized, placebo-controlled trial. Am J Med. 1996;
171:341-348.
25. Adami S, Mian M, Gatti P, Rossini M, Zaamberlan N, Bertoldo F,
Lo Cascio V. Effect of two oral dose of alendronate in the treat-
ment of Paget’s disease of bone. Bone. 1994;15:415-417.
26. Miller PD, Adachi JD, Brown JP, Khairi RA, Lang R, Licata AA,Mc-
Clung MR, Ryan WG, Singer FR, Siris ES, Tenenhouse A, Wal-
lach S, Bekker PJ, Axelrod DW. Risedronate vs. etidronate:
durable remission with only two months of 30 mg risedronate. J
Bone Miner Res. 1997;12:S269.
27. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang
R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR,
Tucci JR, Eusebio RA, Bekker PJ. Risedronate in the treatment of
Paget’s disease: an open-label, multicenter study. J Bone Miner
Res. 1998;13:1032-1038.
28. Filipponi P, Pedetti M, Beghé F, Giovagnini B, Miam M, Cristallini
S. Effects of two different bisphosphonates on Paget’s disease of
bone: ICTP assessed. Bone. 1994;15:261-267.
222 Clinical Cases in Mineral and Bone Metabolism 2004; 1(3): 219-222
S.Adami et al.
FOR
 REV
IEW
ONL
Y
© CI
C ED
IZION
I INT
ERN
AZIO
NALI
